Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.5935/2595-0118.20190068
Brazilian Journal of Pain
Artigo de Revisão

Pharmacological treatment of pain in pregnancy

Tratamento farmacológico da dor na gestante

Fábio Farias de Aragão; Alexandro Ferraz Tobias

http://dx.doi.org/10.5935/2595-0118.20190068 BrJP, vol.2, n4, p.374-380, 2019
PDF English
PDF Português
SciELO
Downloads: 2
Views: 584

Abstract

BACKGROUND AND OBJECTIVES: Non-obstetric causes of pain during pregnancy are very common and can be disabling if not treated properly. The objective of this study is to discuss the pharmacological treatment of pain during pregnancy with a focus on drug classification and pregnancy use, therapy options, teratogenicity, increased fetal malformations and gestational complications associated with the use of therapy. 

CONTENTS: During pregnancy, the body goes through several anatomical and physiological changes. These changes can precipitate pain, which in some cases can lead to disability. In addition, pregnancy may exacerbate pre-existing painful conditions. The choice to prescribe a drug to a pregnant woman is difficult. The changes in the body of a pregnant woman influence drug absorption, distribution, metabolism, and excretion, and may alter the expected response.

CONCLUSION: The risks and benefits of the drug for the mother and the child should be considered, weighing the risks of not treating the disease adequately during pregnancy.

Keywords

Analgesic, Pain treatment, Pregnancy

Resumo

JUSTIFICATIVA E OBJETIVOS: As causas não obstétricas de dor durante a gravidez são muito comuns e podem ser incapacitantes se não forem tratadas adequadamente. O objetivo deste estudo foi discutir o tratamento farmacológico da dor durante o período gestacional com foco na classificação de fármacos e o uso na gravidez, opções de terapia, teratogenicidade, aumento de malformações fetais e complicações gestacionais associados ao uso da terapia.

CONTEÚDO: Durante a gravidez, várias alterações anatômicas e fisiológicas ocorrem no corpo. Essas alterações podem precipitar a dor, que em alguns casos pode levar à incapacidade. Além disso, a gravidez pode exacerbar condições dolorosas pré-existentes. A escolha de prescrever um fármaco para uma gestante é difícil. As alterações gravídicas no corpo da gestante influem na absorção, distribuição, metabolismo e excreção dos fármacos, podendo alterar a resposta esperada.

CONCLUSÃO: Deve-se considerar os riscos e benefícios do uso do fármaco para a mãe e filho, pesando-se os riscos de não tratar adequadamente a doença durante a gestação.

Palavras-chave

Analgésicos, Gestação, Tratamento da dor

Referências

Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology. 2014;120(5):1216-24.

Shah S, Banh ET, Koury K, Bhatia G, Nandi R, Gulur P. Pain management in pregnancy: multimodal approaches. Pain Res Treat. 2015;2015:987483.

Teratology public affairs committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defects Res A Clin Mol Teratol. 2007;79(9):627-30.

Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information?. Drug Saf. 2000;23(3):245-53.

Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. 2007.

IV Diretrizes Brasileiras para o Manejo da Asma. J Bras Pneumol. 2006;32(^sSupl Suppl 7):S447-74.

Wilmer E, Chai S, Kroumpouzos G. Drug safety: pregnancy rating classifications and controversies. Clin Dermatol. 2016;34(3):401-9.

Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist. 2014;79(233):72064-103.

Pregnancy, lactation, and reproductive potential: labeling for human prescription drug and biological products--content and format: guidance for industry. 2014.

Rocha R, Rennó Júnior J, Ribeiro HL, Cavalsan AP, Cantilino A, Mendes-Ribeiro JA. Medicamentos na gravidez e lactação: novas normas do FDA. Rev Debate em Psiquiatria. 2015:28-32.

Toda K. Is acetaminophen safe in pregnancy?. Scand J Pain. 2017;17:445-6.

Arendrup FS, Mazaud-Guittot S, Jégou B, Kristensen DM. EDC IMPACT: Is exposure during pregnancy to acetaminophen/paracetamol disrupting female reproductive development?. Endocr Connect. 2018;7(1):149-58.

Rebordosa C, Zelop CM, Kogevinas M, Sørensen HT, Olsen J. Use of acetaminophen during pregnancy and risk of preeclampsia, hypertensive and vascular disorders: a birth cohort study. J Matern Fetal Neonatal Med. 2010;23(5):371-8.

da Silva Dal Pizzol T, Schüler-Faccini L, Mengue SS, Fischer MI. Dipyrone use during pregnancy and adverse perinatal events. Arch Gynecol Obstet. 2009;279(3):293-7.

Sharpe CR, Franco EL. Use of dipyrone during pregnancy and risk of Wilm's tumor. Epidemiology. 1996;7(5):533-5.

Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001;61(6):2542-6.

Izumi K, Sano N, Otsuka H, Kinouchi T, Ohnishi Y. Tumor promoting potential in male F344 rats and mutagenicity in Salmonella typhimurium of dipyrone. Carcinogenesis. 1991;12(7):1221-5.

Giri AK, Mukhopadhyay A. Mutagenicity assay in Salmonella and in vivo sister chromatid exchange in bone marrow cells of mice for four pyrazolone derivatives. Mutat Res. 1998;420(1-3):15-25.

Dathe K, Padberg S, Hultzsch S, Meixner K, Tissen-Diabaté T, Meister R. Metamizole use during first trimester-A prospective observational cohort study on pregnancy outcome. Pharmacoepidemiol Drug Saf. 2017;26(10):1197-204.

Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063-75.

Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review from the U.S. Preventative Services Task Force. Ann Intern Med. 2014;160(10):695-703.

van Vliet EO, Askie LA, Mol BW, Oudijk MA. Antiplatelet agents and the prevention of spontaneous preterm birth: a systematic review and meta-analysis. Obstet Gynecol. 2017;129(2):327-36.

Werler MM, Mitchell AA, Moore CA, Honein MA. Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis?. Am J Med Genet A. 2009;149A(7):1399-406.

Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791-8.

Mone F, Mulcahy C, McParland P, McAuliffe FM. Should we recommend universal aspirin for all pregnant women?. Am J Obstet Gynecol. 2017;216(2):141.e1-5.

Nakhai-Pour HR, Broy P, Sheehy O, Bérard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183(15):1713-20.

Edwards DR, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-in: ammatory drug exposure and risk of spontaneous abortion. Obstet Gynecol. 2012;120(1):113-22.

Daniel S, Koren G, Lunenfeld E, Levy A. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiin?ammatory drug exposure. Am J Obstet Gynecol. 2015;212(3):307.e1-6.

Daniel S, Koren G, Lunenfeld E, Bilenko N, Ratzon R, Levy A. Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions. CMAJ. 2014;186(5):177-82.

Norman RJ, Wu R. The potential danger of COX-2 inhibitors. Fertil Steril. 2004;81(3):493-4.

Lind JN, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics. 2017;139(6).

Cleves MA, Savell Jr VH, Raj S, Zhao W, Correa A, Werler MM. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects. Birth Defects Res Part A Clin Mol Teratol. 2004;70(3):107-13.

Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063-75.

Østensen ME, Skomsvoll JF. Anti-inflammatory pharmacotherapy during pregnancy. Expert Opin Pharmacother. 2004;5(3):571-80.

Sawdy RJ, Lye S, Fisk NM, Bennett PR. A double-blind randomized study of fetal side effects during and after the short-term maternal administration of indomethacin, sulindac, and nimesulide for the treatment of preterm labor. Am J Obstet Gynecol. 2003;188(4):1046-51.

Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-30.

Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011;204(4):314.e1-11.

Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol. 2013;122(4):838-44.

Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67(12):1253-61.

Källén B, Reis M. Use of tramadol in early pregnancy and congenital malformation risk. Reprod Toxicol. 2015;58:246-51.

Källén B, Reis M. Ongoing pharmacological management of chronic pain in pregnancy. Drugs. 2016;76(9):915-24.

Bloor M, Paech MJ, Kaye R. Tramadol in pregnancy and lactation. Int J Obstet Anesth. 2012;21(2):163-7.

Kraychete DC, Siqueira JT, Zakka TR, Garcia JB. Recommendations for the use of opioids in Brazil: Part III. Use in special situations (postoperative pain, musculoskeletal pain, neuropathic pain, gestation and lactation). Rev Dor. 2014;15(2):126-32.

Regan J, Chambers F, Gorman W, MacSullivan R. Neonatal abstinence syndrome due to prolonged administration of fentanyl in pregnancy. BJOG. 2000;107(4):570-2.

Cohen RS. Fentanyl transdermal analgesia during pregnancy and lactation. J Hum Lact. 2009;25(3):359-61.

Kaltenbach K, O'Grady KE, Heil SH, Salisbury AL, Coyle MG, Fischer G. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug Alcohol Depend. 2018;185:40-9.

Lalkhen A, Grady K. Non-obstetric pain in pregnancy. Rev Pain. 2008;1(2):10-4.

Bérard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7.

Ornoy A, Weinstein-Fudim L, Ergaz Z. Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression. Birth Defects Res. 2017;109(12):933-56.

Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938-46.

Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population-based cohort study and sibling design. BMJ. 2015;17(350).

Andrade C. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry. 2014;75(12):e1423-7.

Hara T, Nakajima M, Sugano H, Karagiozov K, Hirose E, Goto K. Pregnancy and breastfeeding during intrathecal baclofen therapy - case study and review. NMC Case Rep J. 2018;25:65-8.

Moreira A, Barbin C, Martinez H, Aly A, Fonseca R. Maternal use of cyclobenzaprine (Flexeril) may induce ductal closure and persistent pulmonary hypertension in neonates. J Matern Fetal Neonatal Med. 2014;27(11):1177-9.

Díaz RR, Rivera AL. Manejo del dolor no obstétrico durante el embarazo. Artículo de revisión. Rev Colomb Anestesiol. 2012;40(3):213-23.

Weston Z, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016.

Andrade C. Adverse pregnancy outcomes associated with gestational exposure to antiepileptic drugs. J Clin Psychiatry. 2018;31(4).

Patorno E, Bateman BT, Huybrechts KF, MacDonald SC, Cohen JM, Desai RJ. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017;23(21):2020-5.

Submetido em:
14/12/2018

Aceito em:
28/02/2019

5f248fd20e88254d23e56d7d brjp Articles
2595-3192 (Eletrônico) 2595-0118 (Impresso)
BrJP ©2024 Todos os direitos reservados.

BrJP

Share this page
Page Sections